Divyaxa Agnihotri

Am I audible?

Hello. Yes, so congratulations on the insulin portfolio growth, actually. I just had one question around that. So, what I wanted to understand is probably threat of new entrants. So, you have Novo Nordisk with Awiqli , which has come out, which is a higher insulin unit dosage format for long-acting basal insulin injections.

Inherently, do you think like the insulin market right now for Lantus and Toujeo, which is once a day basal insulin injections, is this market that at least sticky in the sense that existing patient base is not going to be as affected, by and also having scope for adding newer patients and these sort of newer entrants, regardless of sort of different, them having different patient profiles, it's not going to be…